Filgrastim Biosimilars Market Growth Outlook Reveals A CAGR Of 11.9% And A Market Value Of $2.08 Billion By 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Filgrastim Biosimilars Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for filgrastim biosimilars has experienced rapid expansion in recent years. Projected to climb from $1.19 billion in 2025 to $1.33 billion in 2026, this represents a compound annual growth rate (CAGR) of 11.5%. Factors driving historical growth include the elevated expense of the original filgrastim, a rise in cases of cancer and blood-related conditions, restricted availability of biologic therapies in developing areas, advancements in hospital infrastructure, and the timely authorization of biosimilars by regulatory agencies.
The filgrastim biosimilars market is projected to experience substantial expansion over the coming years, reaching an estimated value of $2.09 billion by 2030, which represents a compound annual growth rate of 11.9%. This anticipated growth during the forecast period is driven by several key factors, including the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing partnerships, a growing rate of adoption for treating chronic and autoimmune diseases, strengthened government support combined with favorable reimbursement policies, and the creation of patient-focused distribution and delivery systems. Among the major trends shaping this period are the increasing use of filgrastim biosimilars within oncology and blood disorder therapies, the growth of contract manufacturing organizations dedicated to biosimilar production, a stronger reliance on vertically integrated in-house manufacturing setups, a rising preference for distribution through hospital and retail pharmacy channels, and an overall emphasis on delivering cost-effective biologic treatments while improving market access.
Download A Free Sample Report For Comprehensive Market Insights:
Filgrastim Biosimilars Market Growth Momentum: Which Factors Are Influencing Demand?
The growth of the filgrastim biosimilars market is anticipated to be fueled by the increasing prevalence of cancer in the coming years. Cancer encompasses a range of illnesses characterized by the abnormal proliferation and spread of cells within the body, resulting from genetic mutations that impair normal cellular regulation. The higher occurrence of cancer is partially attributed to an aging population, as longer lifespans elevate the probability of genetic mutations that can trigger the disease. By enhancing white blood cell production, filgrastim biosimilars assist cancer patients in lowering the risk of neutropenia caused by chemotherapy, thereby facilitating more consistent and safer treatment. As an example, in October 2025, the National Health Service (NHS), a government health authority in the UK, reported that 354,820 new cancer cases were diagnosed in 2023—an average of 972 per day, representing an increase of 8,605 compared to 2022. Consequently, the uptick in cancer incidence is propelling the filgrastim biosimilars market forward.
Filgrastim Biosimilars Market Segment Analysis And Revenue Opportunities
The filgrastim biosimilars market covered in this report is segmented –
1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services
Filgrastim Biosimilars Market Trends Reshaping Industry Growth
Leading firms within the filgrastim biosimilar space are currently focusing on the creation of innovative products that rely on advanced methodologies, including recombinant DNA technology, to manufacture biosimilars. This technology involves assembling hybrid or chimeric DNA by introducing a foreign sequence into the genetic material of an organism. As an example, in May 2023, Amneal Pharmaceuticals—a pharmaceutical company headquartered in the US—released FYLNETRA (pegfilgrastim-pbbk), a biosimilar comparable to Amgen’s NEULASTA, available in the United States for managing and preventing febrile neutropenia. This agent facilitates the growth and specialization of neutrophils from dedicated precursor cells, triggers their maturation process, and boosts both the viability and effectiveness of mature neutrophils, resulting in dose-dependent elevations in neutrophil counts. By launching Fylnetra, the next generation of cost-effective treatments is advanced, broadening access for patients, healthcare providers, and insurers alike.
Filgrastim Biosimilars Market Leading Players Shaping Industry Direction
Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.
Access The Complete Filgrastim Biosimilars Market Report:
Filgrastim Biosimilars Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
